Clinical trials: SARS
Coronavirus Infections
French COVID Cohort
Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus, novel influenza viruses, viruses causing viral haemorrhagic fever (e.g.
- Trial name
- FrenchCOVID (NCT04262921)
- Where
- 98 sites in France
- Volunteers
- 4,415 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Respiratory Infections, Antibiotic
Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing
Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV).
- Trial name
- TROD-VILLE (NCT07243249)
- Testing
- TROD
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19.
- Trial name
- NCT04362189
- Testing
- HB-adMSC
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hope Biosciences Research Foundation
Sars-CoV-2 Infection, COVID-19
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
SARS-CoV-2 rapid antigen over the counter usability study.
- Trial name
- NCT05584189
- Testing
- Rapid SARS-CoV-2 Antigen Test
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- MP Biomedicals, LLC
COVID-19 Pandemic
Research on Community Based ATK Test Study to Control Spread of COVID-19 in Migrant Community
Thousands of migrants from Myanmar have arrived in Thailand for their safety, better living standards and employment opportunities. They are often in Thailand illegally and have poor access to the Thai health care system.
- Trial name
- CATK (NCT05557513)
- Testing
- STANDARD Q COVID-19 Ag Test
- Where
- Thailand
- Volunteers
- 1,310 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19; and High Infection Risk of SARS-CoV-2
Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese…
- Trial name
- NCT04441918
- Testing
- JS016 (anti-SARS-CoV-2 monoclonal antibody)
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Pneumonia
Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin…
- Trial name
- RECOVERY (NCT04381936)
- Testing
- Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine
- Where
- 16 sites in Belgium, Estonia and 14 more
- Volunteers
- 70,000 people
- Sponsor
- University of Oxford
Cholangitis, Secondary Biliary, Cholangiocarcinoma
Advanced Endoscopy During COVID-19
In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.
- Conditions
- Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer
- Trial name
- NCT04385147
- Testing
- Endoscopic management according to standard of care
- Where
- 5 sites in United States, Egypt and 3 more
- Volunteers
- 670 people
- Sponsor
- Al-Azhar University
Immune Response
Comparative Analysis of Anti-COVID-19 (Severe Acute Respiratory Syndrome) Humoral and Memory T Cell Responses in Children With Various Degrees of Immunosuppression:
Adaptive immune responses are essential for clearing viral infections and retention of virus specific memory populations is required for long-term immunity.
- Trial name
- PEDIMMCO (NCT04916847)
- Testing
- blood collection
- Where
- France
- Volunteers
- 205 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV-2 Infection, Influenza A
Project STARFISH - PRJ0002679
This is a non-interventional study to perform the clinical performance evaluation of the Starfish Test using prospectively collected matched nasopharyngeal and nasal swab samples from the same donor.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
- Trial name
- STARFISH (NCT05727202)
- Testing
- The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
- Where
- 17 sites in United States
- Volunteers
- 1,909 people
- Sponsor
- Thermo Fisher Scientific, Inc
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
The objective of the study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E, comparing the immunogenicity data against Beta (B.1.351), Delta (B.1.617.2), Omicron (B.1.1.529) and other variants with Sinopharm…
- Trial name
- NCT05308602
- Testing
- SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Convalescent Plasma Therapy - Zurich Protocol
This is an open-label, single-center, phase I study to assess the safety and efficacy of convalescent plasma therapy (CPT) obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection and…
- Trial name
- CPT-ZHP (NCT04869072)
- Testing
- Convalescent plasma
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
Vaccine Refusal, Covid19
Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California
The United States (U.S.) is the country with the largest number of infections and deaths due to COVID- 19 and racial/ethnic minorities are disproportionately affected.
- Trial name
- 2VIDA! (NCT05022472)
- Testing
- COVID-19 Individual Awareness and Education., COVID-19 Community Outreach & Health Promotion., COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.
- Where
- 6 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- Britt Skaathun
Myocarditis, Pericarditis
A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
The main goal of this study is to describe the clinical course, outcomes and risk factors for myocarditis and pericarditis associated with Moderna vaccination targeting SARS-CoV-2.
- Trial name
- NCT06113692
- Testing
- mRNA-1273
- Where
- 5 sites in Denmark, Norway and 2 more
- Volunteers
- 1,169 people
- Sponsor
- ModernaTX, Inc.
SARS-Cov-2, Covid19
Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood
Prospective, multi-center, observational, blinded clinical trial to compare a new point of care (POC) SARS-CoV-2 IgG antibody test to a reference SARS-CoV-2 PCR test using fingerstick whole blood.
- Trial name
- NCT04699903
- Testing
- POC SARS-Cov-2 IgG Antibody test
- Where
- 3 sites in United States
- Volunteers
- 201 people
- Sponsor
- Lumos Diagnostics
SARS-CoV-2, COVID-19
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID…
- Conditions
- SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- NCT05876377
- Testing
- Pfizer-BioNTech COVID-19 mRNA vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Covid19
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged…
- Trial name
- COVID-19 (NCT04863638)
- Testing
- 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Viral Respiratory Infection (e.g., Influenza), Bacterial Respiratory Infections
Respiratory Pathogen Distribution During and After the COVID-19 Pandemic
This retrospective observational study aims to evaluate changes in the prevalence and distribution of respiratory pathogens detected by multiplex respiratory polymerase chain reaction (PCR) testing during and after the SARS-CoV-2…
- Trial name
- NCT07601126
- Where
- Turkey (Türkiye)
- Volunteers
- 537 people
- Sponsor
- Hisar Intercontinental Hospital
COVID, Corona Virus Infection
Seroprevalence of SARS-Cov-2 Antibodies in Children
It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to…
- Conditions
- COVID, Corona Virus Infection, Multisystem Inflammatory Syndrome in Children
- Trial name
- NCT04347408
- Testing
- Covid-19 Antibody testing (IgG and IgM), Blood Storage
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
COVID-19, Upper Respiratory Tract Infections
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours.
- Trial name
- NCT05252468
- Testing
- TaffiX™
- Where
- Bulgaria
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma